Adhera Therapeutics, Inc. (ATRX)
Chart Events
Performance Outlook
| Previous Close | 0.0550 |
| Open | 0.0600 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.0570 - 0.0700 |
| 52 Week Range | 0.0400 - 0.4800 |
| Volume | |
| Avg. Volume | 31,627 |
| Market Cap | 989,810 |
| Beta (5Y Monthly) | -0.07 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.6270 |
| Earnings Date | Jul 06, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Adhera Therapeutics Appoints Trond K. Waerness as Chairman of the Board, Company Focuses on Uplist to NASDAQ
Baton Rouge, LA, May 19, 2022 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCQB: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, is pleased to announce the appointment of Trond K. Waerness as Chairman of the Company’s Board of Directors. Mr. Waerness has been serving as a Director at Adhera since April 2021. Mr. Waerness is a pharmaceutical executive with approximately 25 years of experience in all areas of pharmaceutical commercialization. He has held roles in
- GlobeNewswire
Adhera Therapeutics Names Preeminent Diabetes Pioneer Dr. Jean Buteau to Scientific Advisory Board
Baton Rouge, LA, March 21, 2022 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, is pleased to announce the appointment of Jean Buteau, PhD., to the Company’s Scientific Advisory Board. Dr. Buteau, a published scientist, and award-winning pioneer in the field of diabetes, will lend his expertise and oversight to help advance Adhera’s pipeline, including MLR-1023, the Company’s Phase 2-ready drug candidate as a no
- GlobeNewswire
Adhera Therapeutics Announces Uplisting to OTCQB Venture Marketplace
Baton Rouge, LA, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, is pleased to announce its successful uplisting from the OTC Pink Sheets to the OTCQB® Venture Marketplace (the “OTCQB”). Adhera will commence trading on the OTCQB at the market open on January 20, 2022 under the ticker “ATRX.” The Company believes that the uplist will create greater visibility to retail and institutional investors, a
